Related Experiment Video
Updated: Jul 4, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Genetic alterations of HLA-class II in ovarian cancer
Kirsten Kübler1, Peter F Arndt, Eva Wardelmann
1Department of Obstetrics and Gynecology, University of Bonn, Sigmund Freud Strasse 25, 53127 Bonn, Germany.
Abstract:
The immune system controls tumor formation through identification and elimination of cellular alterations. Consequently, cancer development in immune competent hosts depends on strategies to evade the immune system. Modulation of tumor antigen-specific immune responses by aberrant expression of HLA-class I and II molecules is well documented in a variety of carcinomas including ovarian cancer. To date, little data are available about molecular mechanisms responsible for altered HLA-class II phenotypes in tumors. In our sample of 10 Caucasian patients with ovarian carcinoma, a semiquantitative analysis was performed for HLA-class II loci DRB1 and DQB1 in malignant and normal ovarian tissue. Gene amplifications were identified in 62.5% of analyzed alleles and deletions in 17.5%, demonstrating that genomic aberrations of 6p21.3 are common and that copy number gain is more frequent than loss. Moreover, amplifications are most pronounced in advanced-stage tumors. To evaluate genotype-phenotype relation, immunohistochemical analyses were performed and revealed de novo expression of HLA-class II in 30% of tumors with an inverse association between antigen level and HLA copy number. It remains to be elucidated whether the profound changes of the latter quantities are the result of the host's immunological self-defense, indicate the presence of an oncogene located within the MHC-complex or merely reflect the increasing loss of differentiation of the tumor tissue.
Insights
Genomic alterations in HLA-class II genes are common in ovarian cancer, with amplifications more frequent than deletions, particularly in advanced stages. These changes impact tumor immune evasion strategies.
Area of Science:
- Immunology
- Oncology
- Genetics
Background:
- The immune system eliminates cellular alterations, preventing tumor formation.
- Cancer evasion strategies involve modulating immune responses, often through Human Leukocyte Antigen (HLA) expression.
- Aberrant HLA-class II expression is noted in ovarian cancer, but underlying molecular mechanisms are unclear.
Purpose of the Study:
- To investigate the frequency and nature of genomic aberrations in HLA-class II loci (DRB1 and DQB1) in ovarian carcinoma.
- To correlate these genomic changes with HLA-class II expression phenotypes.
- To explore the implications of these alterations in tumor immune evasion.
Main Methods:
- Semiquantitative analysis of HLA-class II loci DRB1 and DQB1 in tumor and normal ovarian tissues from 10 patients.
- Analysis of gene amplifications and deletions at the 6p21.3 locus.
- Immunohistochemical analysis to assess HLA-class II expression and its relation to gene copy number.
Main Results:
- Genomic aberrations of 6p21.3 are common in ovarian carcinoma, with amplifications in 62.5% and deletions in 17.5% of alleles.
- Gene copy number gain is more frequent than loss, and amplifications are more pronounced in advanced-stage tumors.
- De novo expression of HLA-class II was observed in 30% of tumors, showing an inverse association with HLA copy number.
Conclusions:
- Genomic alterations, particularly amplifications, in HLA-class II loci are frequent in ovarian cancer and associated with tumor stage.
- The observed genotype-phenotype relationship suggests complex regulatory mechanisms influencing HLA-class II expression.
- Further research is needed to determine if these genomic changes are driven by immune self-defense, oncogenes, or tumor dedifferentiation.
Related Concept Videos
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...